OBJECTIVE:To probe into the clinical effects of imatinib in treatment of advanced malignant melanoma with C-kit and B-raf gene mutation .METHODS:124 patients with advanced malignant melanoma tumors admitted from Jan.2010 to Jan.2014 were selected to be divided into observation group and control group via the random number table, with 62 cases in each .The control group were treated with dacarbazine , while the observation group additionally received imatinib based on the control group .All patients were followed up for 2 years.The toxic reactions, efficacy, disease-free survival ( DFS) of two groups were observed , and the one-year and two-year survival rate of two groups were compared .RESULTS:There was no statistical significance between two groups in the adverse drug reactions during the treatment (P>0.05).The disease remission rate of observation group was 6.29%(38/62), significantly higher than that of control group [22.58%(14/62)], with statistically significant difference (P<0.05).The DFS of observation group was (10.2 ±1.1) months, significantly higher than that of control group [(5.1 ±0.3) months], with statistically significant difference (P<0.05).Meanwhile, the one-year and two-year survival rate of observation group was significantly higher than that of control group, with statistically significant difference(P<0.05).CONCLUSIONS:Imatinib in treatment of advanced malignant melanoma with C-kit and B-raf gene mutation can effectively control the rate of disease progression and prolong patients'survival time, without any additional tadverse drug reactions during treatment .%目的：探讨伊马替尼对晚期恶性黑色素瘤C-kit及B-raf基因突变者的临床效果。方法：选择2010年1月—2014年1月收治的124例晚期恶性黑色素瘤患者，按照随机数字法分为观察组和对照组，每组各62例。对照组患者给予达卡巴嗪，观察组在对照组治疗的基础上联合应用伊马替尼，对所有患者随访2年，观察2组患者治疗过程中发生的不良反应、疗效及无病生存时间，并比较2组患者1、2年生存率。结果：2组患者化疗不良反应的差异无统计学意义（ P＞0.05）；观察组患者的疾病缓解率为61.29％（38／62），显著高于对照组的22.58％（14／62），差异有统计学意义（P＜0.05）；观察组患者无病生存时间为（10.2±1.1）个月，显著长于对照组的（5.1±0.3）个月，差异有统计学意义（P＜0.05）；观察组患者1年及2年生存率均明显高于对照组，差异均有统计学意义（P＜0.05）。结论：伊马替尼治疗晚期恶性黑色素瘤C-kit及B-raf基因突变患者，能有效控制疾病进展速度，延长患者生存时间，且不增加治疗过程中的不良反应。
展开▼
